We are live on ! Find out more

16 hedge funds and large institutions have $2.77M invested in IN8bio in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

14% more capital invested

Capital invested by funds: $2.42M → $2.77M (+$342K)

0% more ownership

Funds ownership: 0.16%0.16% (+0%)

6% less funds holding

Funds holding: 1716 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
5
Reduced
4
Closed
5
Calls
Puts
Net Calls
Net Calls Change

INAB Hedge Fund Activity: Q4 2022 in Review

16 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q4 2022, worth a combined $2.77M — up 14% from $2.42M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of INAB and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 5 added.

The largest buyer was Rock Creek Group, opening a new position worth an estimated $152K. The largest seller was Precept Management, exiting entirely with an estimated $101K sold.

  • 16 institutional investors held IN8bio (INAB) as of Q4 2022, down from 17 in Q3 2022.
  • Funds reported $2.77M of IN8bio stock for Q4 2022, up 14% quarter-over-quarter.
  • 4 funds opened new IN8bio positions in Q4 2022 and 5 closed out, a net change of -1 holder.
  • The largest IN8bio buyer in Q4 2022 was Rock Creek Group, an estimated $152K added.
  • The largest IN8bio seller in Q4 2022 was Precept Management, an estimated $101K sold.

Based on aggregated 13F filings for Q4 2022.